Oxford Nanoimaging

Quantum-Si Bolsters Executive Leadership Team with Four Key Appointments

Retrieved on: 
Monday, April 24, 2023
Semiconductor, Health, Technology, Health Technology, Genetics, Pharmaceutical, Biotechnology, Hamamatsu Photonics, Pacific Biosciences, Reagent, Operation, Protein sequencing, Senior, Data science, Marketing, Chief commercial officer, Algorithm, Autocar Sales and Service Building, University of California, Santa Cruz, Oxford Nanoimaging, Research, Genomics, Dicarboxylic acid, Doctor of Philosophy, Proteomics, Protein, UC, Engineering, Epic Sciences, Raytheon Technologies, Drug discovery, Supply, Corisella inscripta, Genetix, Platinum, Management, Fine chemical, Illumina

These appointments follow the commercial launch of Platinum™, the world’s first next-generation, single-molecule protein sequencing platform, and will support Quantum-Si's growing customer base and further scaling of the company.

Key Points: 
  • These appointments follow the commercial launch of Platinum™, the world’s first next-generation, single-molecule protein sequencing platform, and will support Quantum-Si's growing customer base and further scaling of the company.
  • Prior to this, Ms. Atkinson held executive leadership positions at Truvian, Epic Sciences, Edico Genome and Illumina.
  • Mr. Hutcheson has more than 20 years of experience as a commercial professional within the genomics, biotechnology, and drug discovery markets.
  • Its elegant simplicity enables broad-scale access to proteomic data, making it a critical instrument for the future of proteomics research.

ONI Appoints Paul Scagnetti as CEO to Implement Next Chapter of Growth

Retrieved on: 
Monday, February 27, 2023
Medical Devices, Health, Research, Pharmaceutical, Science, Biotechnology, Corporation, Oxford Nanoimaging, Business, Data analysis, Strategic planning, Intel, Growth, Biology, FEI, Multimedia, Microscopy, Management

Along with this leadership change, ONI will begin to implement a new strategy to accelerate commercial growth and expand its impact in research and discovery.

Key Points: 
  • Along with this leadership change, ONI will begin to implement a new strategy to accelerate commercial growth and expand its impact in research and discovery.
  • Paul succeeds founding CEO, Bo Jing, who will remain with ONI as a key contributor in product development to help inspire ONI’s next innovations.
  • The microscopy and data analysis platforms will form a strong basis for us to grow the company and add tremendous value to life scientists,” said incoming CEO Paul Scagnetti.
  • As CEO, Paul will be responsible for driving the company's future growth and expanding its reach to new customers and markets.

ONI and the University of Pennsylvania Start Research Collaboration to Identify Unique Biomarkers and Characteristics to Guide Next Generation CAR-T Development

Retrieved on: 
Tuesday, October 11, 2022
Stem Cells, Biotechnology, Health, Pharmaceutical, Biometrics, Oncology, Other Science, Medical Devices, Research, Science, Clinical Trials, LinkedIn, Disease, Therapy, University of Oxford, Patient, ACC, HQ, Research, Twitter, University, MD, Toxicity, CEO, Oxford Nanoimaging, Safety, University of Pennsylvania, Nanoparticle, Center, Perelman Center for Advanced Medicine, FDA, Biomarker, Medical imaging

ONI , a single-molecule imaging platform biotech, today announced a research collaboration with the University of Pennsylvania, one of the true pioneers of CAR-T (chimeric antigen t-cell) research and clinical trials.

Key Points: 
  • ONI , a single-molecule imaging platform biotech, today announced a research collaboration with the University of Pennsylvania, one of the true pioneers of CAR-T (chimeric antigen t-cell) research and clinical trials.
  • The collaboration aims to enhance the understanding of CAR-T therapies using super-resolution microscopy, identifying predictive biomarkers and characteristics related to CAR-T treatment efficacy and safety, with the goal of improving patient outcomes.
  • ONIs flagship product, the Nanoimager, will allow these researchers to visualize living cells and track how single molecules interact.
  • For more information, visit oni.bio and follow ONI on Twitter @oniHQ and LinkedIn @ONI.

ONI Closes $75 Million Series B Led by ARCH Venture Partners and Casdin Capital

Retrieved on: 
Thursday, January 20, 2022
Biotechnology, Networks, Finance, Health, Professional Services, Biomarker, Nanoparticle, Research, Technology, Virology, HQ, LinkedIn, Biology, List of life sciences, Adoption, Seminal vesicles, CEO, Learning, Disease, Solution, University of Oxford, ARCH, Section 32, Drug development, Oxford Nanoimaging, Therapy, Neuroscience, Biomedical Research, Cell biology, McGill University Life Sciences Research Complex, Twist Bioscience, Twitter, Engineering, Life, Founder CEO, Pharmaceutical industry, Management, Medical imaging, Fine chemical, ONI, ARCH Venture Partners, ONI, ARCH VENTURE PARTNERS

The round was led by ARCH Venture Partners and Casdin Capital , with participation from Section 32 , ARTIS Ventures , Vertical Venture Partners , Axon Ventures and private investors, including Paul Conley.

Key Points: 
  • The round was led by ARCH Venture Partners and Casdin Capital , with participation from Section 32 , ARTIS Ventures , Vertical Venture Partners , Axon Ventures and private investors, including Paul Conley.
  • ONIs technology democratizes cutting-edge science, enabling researchers to develop new angles to explore and understand the complexity of biological systems at super-resolution, said Keith Crandell, Co-founder and Managing Director at ARCH Venture Partners.
  • ARCH Venture Partners invests in advanced technology companies and is one of the worlds leading early-stage technology venture firms.
  • ARCH invests primarily in companies it co-founds with leading scientists and entrepreneurs, bringing innovations in life sciences and physical sciences to market.

ONI Releases New Extracellular Vesicle Imaging Consumable Kit at the 10th Annual Meeting of the International Society for Extracellular Vesicles (ISEV2021)

Retrieved on: 
Tuesday, May 18, 2021
Technology, Medical devices, Photography, Software, Biotechnology, Other Health, Health, Data management, Optical, Video games, Microscopy, Creative works, Oxford Nanoimaging, Single-molecule experiment, Oni

\xe2\x80\x9cAt ISEV2021, we are highlighting early access to our first consumable product, a plug-and-play solution that can be easily integrated into the workflow for single-molecule characterization of EVs.

Key Points: 
  • \xe2\x80\x9cAt ISEV2021, we are highlighting early access to our first consumable product, a plug-and-play solution that can be easily integrated into the workflow for single-molecule characterization of EVs.
  • ONI\xe2\x80\x99s first product, the Nanoimager, is a desktop-sized, single molecule microscopy platform capable of visualizing, tracking and imaging individual molecules in living cells.
  • ONI was founded in 2016 as a spin-out of Oxford University and has its headquarters in San Diego.
  • For more information, visit oni.bio and follow ONI on Twitter @oniHQ and LinkedIn @ONI .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210518005726/en/\n'

ONI Welcomes Dr Tyler Ralston as Chief Technology Officer

Retrieved on: 
Tuesday, May 18, 2021
Health, Medical devices, Technology, Nanotechnology, Research, Science, Biotechnology, Oxford Nanoimaging, T, Microscopy, Publications, Science and technology in the Netherlands, Mass media

b'ONI, a rapidly growing company redefining the boundaries of microscopy with its Nanoimager platform that enables imaging of individual molecules in living cells, today announced that Tyler Ralston, PhD, has joined the company as Chief Technology Officer (CTO).

Key Points: 
  • b'ONI, a rapidly growing company redefining the boundaries of microscopy with its Nanoimager platform that enables imaging of individual molecules in living cells, today announced that Tyler Ralston, PhD, has joined the company as Chief Technology Officer (CTO).
  • In this role, Dr. Ralston will provide leadership, strategic vision and oversee the research and development for advancing ONI\'s technology.
  • View the full release here: https://www.businesswire.com/news/home/20210518005450/en/\n"We are delighted to welcome Tyler to the ONI team.
  • For more information, visit oni.bio and follow ONI on Twitter @oniHQ and LinkedIn @ONI .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210518005450/en/\n'